Sponsor Pipeline

Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. Clinical Trial Pipeline

Data updated daily from ClinicalTrials.gov — last refresh 2026-08-16
3
Active Trials
0
Recruiting
1
Phase 3
3
Disease Areas
1
Changes, 30 Days
What Changed in the Last 30 Days
DetectedTrialChange
2026-08-02 NCT06762743
Bioequivalence Study of Two Brivaracetam Oral Solutions in Healthy Adults Under Fasting…		 overall status: Enrolling by Invitation → Unknown
Active Trials by Phase
Phase 3
1
Phase 2
1
Phase 1
1
Active Trials
NCT IDTitleConditionStatus
Phase 3
NCT06759857 FHND9041 Versus Afatinib for Non-small Cell Lung Cancer Non Small Cell Lung Cancer Enrolling by Invitation
Phase 2
NCT07138014 FHND1002 for ALS Treatment: Phase 2 Amyotrophic Lateral Sclerosis (ALS) Not Yet Recruiting
Phase 1
NCT06782958 Safety, Tolerability, and Pharmacokinetics of FHND1002 Granules in Healthy Adults Amyotrophic Lateral Sclerosis (ALS) Enrolling by Invitation
Disease Areas
ALS (2) Non-Small Cell Lung Cancer (NSCLC) (1) Lung Cancer (1)
Get alerts when Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd.'s trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free